Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
[PubMed - indexed for MEDLINE]
2.

How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kobys T, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Nehrych T, Moskovko S, Panayiotou P, Jazbec SŠ, Sokolova L, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Voloshyná N, Havrdová E.

Front Neurol. 2013 May 1;4:10. doi: 10.3389/fneur.2013.00010. eCollection 2013.

PMID:
23641231
[PubMed]
Free PMC Article
3.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T.

CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.

PMID:
23607697
[PubMed - indexed for MEDLINE]
4.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
[PubMed - indexed for MEDLINE]
5.

Natalizumab in the treatment of pediatric multiple sclerosis.

Talab R, Talabova M, Klzo L.

Neuro Endocrinol Lett. 2012;33(6):579-89.

PMID:
23160229
[PubMed - indexed for MEDLINE]
6.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
[PubMed - indexed for MEDLINE]
7.

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.

Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E.

Wien Med Wochenschr. 2012 Aug;162(15-16):354-66. Epub 2012 Aug 16. Review. Erratum in: Wien Med Wochenschr. 2013 May;163(9-10):251. Multiple author names added.

PMID:
22895849
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Marburg variant multiple sclerosis - a case report.

Talab R, Kundrata Z.

Neuro Endocrinol Lett. 2011;32(4):415-20.

PMID:
21876497
[PubMed - indexed for MEDLINE]
9.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
[PubMed - indexed for MEDLINE]
10.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group.

Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.

PMID:
21280077
[PubMed - indexed for MEDLINE]
11.

An electrophysiological study of visual processing in spinocerebellar ataxia type 2 (SCA2).

Kremlacek J, Valis M, Masopust J, Urban A, Zumrova A, Talab R, Kuba M, Kubova Z, Langrova J.

Cerebellum. 2011 Mar;10(1):32-42. doi: 10.1007/s12311-010-0220-7.

PMID:
20927662
[PubMed - indexed for MEDLINE]
12.

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group.

Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8.

PMID:
20834039
[PubMed - indexed for MEDLINE]
13.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group.

N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

PMID:
20089960
[PubMed - indexed for MEDLINE]
Free Article
14.

Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.

Talab R, Valis M, Rehak S, Krejsek J.

Neuro Endocrinol Lett. 2009;30(5):647-51.

PMID:
20035270
[PubMed - indexed for MEDLINE]
15.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10.

PMID:
19748319
[PubMed - indexed for MEDLINE]
16.

Diagnosis and surgical therapy of plasma cell neoplasia of the spine.

Rehak S, Maisnar V, Malek V, Cesak T, Ryska P, Bartos M, Talab R.

Neoplasma. 2009;56(1):84-7.

PMID:
19152251
[PubMed - indexed for MEDLINE]
17.

Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.

Valis M, Talab R, Stourac P, Andrys C, Masopust J.

Neuro Endocrinol Lett. 2008 Dec;29(6):971-6.

PMID:
19112391
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators.

Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

PMID:
18970976
[PubMed - indexed for MEDLINE]
19.

The role of embolization in radical surgery of renal cell carcinoma spinal metastases.

Rehák S, Krajina A, Ungermann L, Ryska P, Cerný V, Taláb R, Kanta M, Bartos M.

Acta Neurochir (Wien). 2008 Nov;150(11):1177-81; discussion 1181. doi: 10.1007/s00701-008-0031-5. Epub 2008 Oct 29.

PMID:
18958386
[PubMed - indexed for MEDLINE]
20.

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; Ustekinumab MS Investigators.

Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.

PMID:
18703004
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk